ALS Drug Development Summit 2024

Date: May 21-23, 2024
Location: Boston, MA

ADVANCING PATIENT-CENTRIC DRUG DELIVERY FOR ALS 

In the evolving landscape of patient-centric drug development, innovators are increasingly prioritizing patient-friendly dosage forms, such as ODTs, from the early stages of drug design. ODTs offer convenience and ease of administration, along with addressing concerns about dysphagia and enhancing patient compliance. This event will provide you with a unique opportunity to meet face-to-face with the Catalent team to learn more about how we can help accelerate your product’s potential with Zydis ODT. Schedule a meeting with Michael Sarmento or David Sebesta, Senior Directors, Zydis ODT, to learn more.  

WE LOOK FORWARD TO SEEING YOU IN BOSTON  

The ALS treatment landscape is surging with novel innovation to navigate the complex, multifactorial nature of motor neuron degeneration and develop more truly transformative drugs for sporadic and familial ALS. Capitalizing on rapid pipeline progress and emerging industry investment, join Catalent at the ALS Drug Development Summit in Boston to engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.